49 completed, 8 terminated, 4 withdrawn, 2 unknown. 64 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 64 | Completed 49, Terminated 8, Withdrawn 4, Unknown 2, Recruiting 1 |
Follow Shire: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Replagal in Children and Adults With Fabry Disease in India Replagal - Fabry Disease | Phase 4 | Recruiting | Shire | 5 | 2022-11-01 | 2026-09-03 |
| ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study ARALAST NP - Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency | Phase 4 | Withdrawn | Shire | 2021-03-08 | 2020-09-14 | |
| A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD) Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo - Attention Deficit Hyperactivity Disorder | Phase 4 | Completed | Shire | 396 | 2019-09-18 | 2026-04-13 |
| Guanfacine Extended Release and Mindfulness Skills Therapy Guanfacine Extended Release, Mindfulness Skills Therapy, Placebo - Stress Disorder | Phase 4 | Withdrawn | UConn Health | 2019-03-01 | 2021-03-08 | |
| Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease Lifitegrast - Ocular Discomfort, Ocular Inflammation | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2019-01-01 | 2019-05-17 | |
| Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers Lifitegrast - Contact Lens Dry Eye | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2018-11-01 | 2018-10-25 | |
| Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Lisdexamfetamine Dimesylate - Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder | Phase 4 | Completed | JPM van Stralen Medicine Professional | 48 | 2018-09-26 | 2024-02-12 |
| Different Effects of Non-calcium Phosphate Binders on Serum Calcium Sevelamer Hydrochloride, Lanthanum Carbonate - Chronic Kidney Disease | Phase 4 | Completed | Medical University of Lodz | 34 | 2018-03-01 | 2021-07-27 |
| A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE) rhPTH (1-84), Placebo - Hypoparathyroidism | Phase 4 | Completed | Shire | 93 | 2018-01-24 | 2023-06-09 |
| Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients Lisdexamfetamine - Lisdexamfetamine | Phase 4 | Unknown | North Dakota State University | 20 | 2017-05-12 | 2018-08-23 |
| Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children Lisdexamfetamine, Placebo - Traumatic Brain Injury, Attention Deficit Disorder | Phase 4 | Completed | Vanderbilt University | 20 | 2017-02-06 | 2020-07-13 |
| IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia IgHy10 - Primary Immunodeficiency | Phase 4 | Completed | University Hospital, Lille | 22 | 2016-11-11 | 2019-06-25 |
| A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism rhPTH(1-84) - Chronic Hypoparathyroidism, Hypoparathyroidism | Phase 4 | Completed | Shire | 39 | 2016-10-27 | 2021-07-28 |
| Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease Velaglucerase alfa, Vitamin D - Gaucher Disease | Phase 4 | Completed | Shire | 21 | 2016-06-29 | 2022-02-01 |
| Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) VPRIV - Gaucher Disease, Type 1 | Phase 4 | Completed | Shaare Zedek Medical Center | 15 | 2016-01-10 | 2022-10-28 |
| Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Elaprase for intravenous (IV) infusion - Hunter Syndrome | Phase 4 | Completed | Shire | 21 | 2015-10-28 | 2026-04-02 |
| Lisdexamfetamine's Effect In ADHD in the Brain and Cognition Lisdexamfetamine - Attention Deficit Hyperactivity Disorder | Phase 4 | Terminated | University of California, Davis | 6 | 2014-02-01 | 2019-12-26 |
| Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Lisdexamfetamine Dimesylate, placebo - Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders | Phase 4 | Completed | Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada | 42 | 2013-04-01 | 2017-08-02 |
| Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity prucalopride, PEG 3350 - Chronic Constipation | Phase 4 | Completed | Shire | 13 | 2013-02-27 | 2021-07-02 |
| The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD Methylphenidate, Placebo - Attention Deficit Hyperactivity Disorder | Phase 4 | Completed | VU University of Amsterdam | 61 | 2013-01-01 | 2016-05-13 |
Showing 20 of 64. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (24) · Bipolar Disorder (4) · Hypotension, Orthostatic (4) · Cognitive Dysfunction (3) · Colitis, Ulcerative (3) · Depression (2) · Dry Eye Syndromes (2) · Gaucher Disease (2) · Hypoparathyroidism (2) · Kidney Failure, Chronic (2) · Mucopolysaccharidosis II (2) · Aggression (1) · Anemia (1) · Angioedema (1) · Angioedemas, Hereditary (1)
Lisdexamfetamine Dimesylate (22) · Guanfacine (9) · Midodrine (5) · Sugars (4) · Mesalamine (3) · Methylphenidate (3) · lanthanum carbonate (3) · Atomoxetine Hydrochloride (2) · Carbamazepine (2) · Glucosylceramidase (2) · idursulfase (2) · lifitegrast (2) · prucalopride (2) · Complement C1 Inhibitor Protein (1) · Erythropoietin (1)
United States (48) · Belgium (8) · Germany (7) · Poland (7) · Spain (6) · United Kingdom (6) · Canada (5) · Hungary (5) · Netherlands (5) · Sweden (5) · France (4) · Italy (4) · Czechia (3) · Portugal (3) · Romania (3)
Ari Zimran (1) · Asima F Zehgeer, MD (1) · Barbara J Coffey, MD, MS (1) · Cynthia N Epperson, MD (1) · Cynthia Neill Epperson, M.D. (1) · Eric Hachulla, MD, PhD (1) · J. Alexander Bodkin Bodkin, MD (1) · Jaap Oosterlaan, Prof. Dr. (1) · James D Lewis, MD, MSCE (1) · Janet Wozniak, MD (1) · Jason J Nichols, OD PhD MPH (1) · Joel L Young, MD (1) · Joel L. Young, M.D. (1) · Joseph Biederman, MD (1)
PMID 26063677, PMID 28980198, PMID 16371674, PMID 17448997, PMID 19519256, PMID 20035583, PMID 20978273, PMID 21173426, PMID 21186969, PMID 21837775, PMID 22780921, PMID 23174471, PMID 23356790, PMID 23945447, PMID 24106804, PMID 24307220, PMID 24793028, PMID 25069799, PMID 25193617, PMID 25295646, PMID 25295648, PMID 25808103, PMID 25902842, PMID 26730446, PMID 27270968, PMID 27372462, PMID 27550732, PMID 28667569, PMID 29361097, PMID 29383572, PMID 29790103, PMID 29989200, PMID 30294708, PMID 30368038, PMID 31310310, PMID 32470230, PMID 32738041, PMID 32801008, PMID 32926603, PMID 33123978, PMID 34585675, PMID 34754193, PMID 35974422, PMID 36018496, PMID 39664231, PMID 40009046, PMID 40711996, PMID 41847596
2004 (1), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2017 (1), 2018 (1), K24DK078228 (1)